Integral Diagnostics (IDX) AGM 2024 summary

Opening remarks and agenda

• Chair welcomed attendees, confirmed quorum, and outlined meeting procedures for both in-person and online participants.

• Introduced board members, auditors, and management, and explained voting and Q&A protocols.

• Emphasis on a values-driven culture prioritizing patients, medical leadership, and value creation for stakeholders.

• Focus on high-acuity, specialist care and serving large, high-growth regional markets in Australia and New Zealand.

Financial performance review

• Operating net profit after tax rose 1.3% to AUD 18.1 million, with a stronger second half and improved EBITDA margins.

• Statutory loss after tax was AUD 60.7 million due to a AUD 71.6 million impairment in New Zealand; revenue grew 6.6% to AUD 469.7 million.

• Net debt reduced to AUD 183.5 million, with net debt/EBITDA trending down to 2.6x.

• Groupwide organic revenue growth of 8.6% YTD September FY25, with Australia at 7.9% and New Zealand at 10.2% in NZD vs pcp.

• FY25 capex expected at $40m–$45m, depreciation ~$49m, and finance costs ~$22m, assuming current rates.

Dividend announcements

• Declared a fully franked dividend of AUD 0.058 per share for FY24, down from AUD 0.06 in FY23, representing nearly 75% of FY24 operating NPAT.